Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Hyo Geun | - |
dc.contributor.author | Lee, Hong Kyu | - |
dc.contributor.author | Kang, Ho Suk | - |
dc.contributor.author | Lim, Hyun | - |
dc.contributor.author | Kim, Joo-Hee | - |
dc.contributor.author | Kim, Ji Hee | - |
dc.contributor.author | Kim, Nan Young | - |
dc.contributor.author | Cho, Seong-Jin | - |
dc.contributor.author | Nam, Eun Sook | - |
dc.contributor.author | Min, Kyueng-Whan | - |
dc.contributor.author | Kwon, Mi Jung | - |
dc.date.accessioned | 2022-07-19T05:12:07Z | - |
dc.date.available | 2022-07-19T05:12:07Z | - |
dc.date.created | 2022-06-03 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/170243 | - |
dc.description.abstract | Although safety concerns regarding proton pump inhibitor (PPI)/H2-receptor antagonists (H2RA) in the incident esophageal cancer have been raised, the Asian-based report is unclear. We investigated the estimated likelihood of incident esophageal cancer—its mortality depending on prior history of PPI/H2RA use—and gastroesophageal reflux disease (GERD) in Koreans. Using the Korean National Health Insurance Service-Health Screening Cohort data (2002–2015), a case–control study was retrospectively conducted, including 811 patients with incident esophageal cancer and 3244 controls matched with sex, age, income, and residence. Propensity score overlap weighting was adjusted to balance the baseline covariates. Overlap propensity score-weighted logistic regression analyses were assessed to determine associations of the prior exposure of PPI/H2RA (current vs. past) and the medication duration (<30-, 30–90-, vs. ≥90-days) with incident esophageal cancer and its mortality among the total participants or those with/without the GERD episodes, after adjusting for multiple covariates including PPI/H2RA. The current exposure to either PPI or H2RA showed higher odds for incident esophageal cancer than the nonuser group ([13.23; 95%CI 10.25–17.06] and [4.34; 95%CI 3.67–5.14], respectively), especially in all adults over the age of 40 years without GERD. Both current and past exposures to PPI showed a decreased probability of mortality compared with those of the nonuser group ([0.62; 95%CI 0.45–0.86] and [0.41; 95%CI 0.25–0.67], respectively). However, current or past exposure to H2RA harbored the mutually different likelihoods for mortality depending on the presence of GERD and old age. This study carefully speculates on the possible link between PPI/H2RA and incident esophageal cancer in the Korean population. Mortality appears to be affected by certain risk factors depending on drug types, exposure history, old age, and the presence of GERD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Min, Kyueng-Whan | - |
dc.identifier.doi | 10.3390/ph15050517 | - |
dc.identifier.scopusid | 2-s2.0-85129722750 | - |
dc.identifier.wosid | 000804357700001 | - |
dc.identifier.bibliographicCitation | Pharmaceuticals, v.15, no.5, pp.1 - 19 | - |
dc.relation.isPartOf | Pharmaceuticals | - |
dc.citation.title | Pharmaceuticals | - |
dc.citation.volume | 15 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 19 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HIGH-GRADE DYSPLASIA | - |
dc.subject.keywordPlus | BARRETTS-ESOPHAGUS | - |
dc.subject.keywordPlus | NEOPLASTIC PROGRESSION | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | REDUCE | - |
dc.subject.keywordAuthor | esophageal cancer | - |
dc.subject.keywordAuthor | H2-receptor antagonist | - |
dc.subject.keywordAuthor | mortality | - |
dc.subject.keywordAuthor | nationwide health insurance research database | - |
dc.subject.keywordAuthor | nested case–control study | - |
dc.subject.keywordAuthor | proton pump inhibitor | - |
dc.identifier.url | https://www.mdpi.com/1424-8247/15/5/517 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.